Trial Profile

A randomised phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metsastatic breast cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabazitaxel (Primary) ; Paclitaxel
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms CONCEPT
Sponsors Sanofi

Most Recent Events

08 Jun 2021 Status changed from recruiting to completed as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
11 Nov 2019 Planned number of patients changed from 90 to 160.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com